A retirement-ready portfolio consists of reliable, income-generating stocks that quietly compound over time. Realty Income (O ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Penserra Capital Management significantly slashed its Pfizer holdings by 67%, selling nearly 15,800 shares, leaving a stake ...

The ASX fell 0.11pc in trade, with 7 of 11 sectors lower. The resources industry was a silver lining; both gold and iron ore ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

In a new weekly update for pv magazine, OPIS, a Dow Jones company, provides a quick look at the main price trends in the ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

If your physician prescribes a new branded drug, though, you and your insurance company have few options. Patent-protected ...

Large unusual trading volume in Pfizer, Inc. (PFE) put options that expire 30 days from now signals investors' bullish ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US ...